SCHEMBL23216869

SCHEMBL23216869

COc1cc(C(F)(F)CCCOS(C)(=O)=O)ccn1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LOX P28300 1/20 0.35
LOXL2 Q9Y4K0 1/20 0.35
SLC22A12 Q96S37 1/20 0.35
KDM4E B2RXH2 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
MMP9 P14780 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
SORT1 Q99523 1/20 0.33
SLC13A5 Q86YT5 1/20 0.31
LIPC P11150 1/20 0.31
PTK2 Q05397 1/20 0.30
GABRA1 P14867 1/20 0.30
GABRG2 P18507 1/20 0.30
GABRB3 P28472 1/20 0.30
MAOA P21397 1/20 0.30
S1PR1 P21453 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29664670 0.79 LOX (0.41) LOXLOXL2SLC22A12ALDH1A1SORT1
SCHEMBL23215087 0.79 LOX (0.41) LOXLOXL2SLC22A12ALDH1A1SORT1
SCHEMBL29664732 0.77 FFAR1 (0.45) LOXLOXL2TSHRSORT1SLC13A5
SCHEMBL23215037 0.77 FFAR1 (0.45) LOXLOXL2TSHRSORT1SLC13A5
SCHEMBL23214882 0.75 LOX (0.38) LOXLOXL2KDM4EALDH1A1SORT1
SCHEMBL29664648 0.75 LOX (0.38) LOXLOXL2KDM4EALDH1A1SORT1
SCHEMBL29664623 0.75 FFAR1 (0.48) LOXLOXL2ALDH1A1LMNASORT1
SCHEMBL23216720 0.75 FFAR1 (0.48) LOXLOXL2ALDH1A1LMNASORT1
SCHEMBL31059722 0.73 ALDH1A1 (0.35) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL13876517 0.73 LOX (0.38) LOXLOXL2SLC22A12SORT1SLC13A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2026-05-21 US disclosed
US-12565501-B2 Muscarinic acetylcholine M1 receptor antagonists CONTINEUM THERAPEUTICS, INC. (US) 2026-03-03 US disclosed
US-20250171455-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2025-05-29 US disclosed
US-20230089921-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS, INC. 2023-03-23 US disclosed
CN-114729044-A Muscarinic acetylcholine M1Receptor antagonists 帕珀莱恩医疗公司 2022-07-08 CN disclosed
WO-2021071843-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS Pipeline Therapeutics, Inc. (US) 2021-04-15 WO disclosed
WO-2021071843-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS Pipeline Therapeutics, Inc. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12565501-B2 Muscarinic acetylcholine M1 receptor antagonists CHRM1, CHRM2, CHRM3 LOX 1263/4885LOXL2 2718/4885SLC22A12 4395/4885
US-20230089921-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM2, CHRM3 LOX 1308/4885LOXL2 2276/4885SLC22A12 3985/4885
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM5, CHRM3 LOX 1208/4885LOXL2 2837/4885SLC22A12 4176/4885
US-20250171455-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM2, CHRM3 LOX 1331/4885LOXL2 2285/4885SLC22A12 3966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.